RxDoctor Payments Data

Maria Buhay Maglunog, MD

Rheumatology · West Covina, CANPI 1699744524

Payments from drug & device makers

$19,873in general payments, 2019–2025

Across 1,105 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$5K
  • Johnson & Johnson$3K
  • AbbVie$2K
  • AstraZeneca$2K
  • Mallinckrodt Hospital Products Inc.$1K
  • Pfizer$1K
  • plus $6K from 21 others

What the payments were for

  • Food & beverage$19,66599%
  • Education$2081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,873 in reported general payments places this provider in the 75th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$72,984
Medicare patients
204
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept105$752,357
KrystexxaPegloticase11$603,699
ProliaDenosumab149$236,530
RinvoqUpadacitinib37$227,878
Humira(Cf) PenAdalimumab26$179,639
XeljanzTofacitinib Citrate22$119,073
Humira PenAdalimumab16$103,747
Cosentyx Sensoready (2 Pens)Secukinumab11$102,110
BenlystaBelimumab17$92,625
EnbrelEtanercept11$82,477
Enbrel MiniEtanercept11$79,654
OtezlaApremilast13$62,165
Evenity (2 Syringes)Romosozumab-Aqqg11$24,214
Diclofenac Sodium47$19,953
MethotrexateMethotrexate Sodium389$8,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa, Prolia, Enbrel, Otezla, Evenity (2 Syringes)$4,542$1,009,085195 claims
AbbVieRinvoq$2,167$227,87837 claims
PfizerXeljanz$1,372$119,07322 claims
GSKBenlysta$204$92,62517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 808 rheumatology providers in California.

Other rheumatology in West Covina

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →